---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-016473"
form_type: "8-K/A"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:03:30.245408+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harrow to acquire Melt Pharmaceuticals for $0.50/share; already owns 45%

## Summary
- Harrow will pay $0.50 per share of Melt Common Stock for the remaining ~55% it does not already own.
- Melt is a clinical-stage company developing MELT-300 for procedural sedation in cataract surgery.
- Transaction approved by special committees of both boards, each receiving fairness opinions.
- Harrow and Melt entered a Milestone Payment Agreement tied to regulatory and sales milestones.
- Merger Sub will merge with and into Melt; Melt will survive as wholly owned subsidiary of Harrow.

## SEC filing metadata
- accession: 0001493152-25-016473
- form_type: 8-K/A
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315225016473/0001493152-25-016473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315225016473/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-016473
- JSON: https://secwatch.observer/filing/0001493152-25-016473.json
- Plain text: https://secwatch.observer/filing/0001493152-25-016473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.